Clinical Trials Listing

Clinical Trials Listing

The following are the currently Active Clinical Trials as of 5/9/2008 3:15:27 PM.

To send email regarding a particular Clinical Trial, click on the underlined Nurse's name.

*Anus*	Top
*Also see Solid Tumor*

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
ECOG E3205		Phase II Trial of Cetuximab Plus Cisplatin, 5-FU and Radiation in Immunocompetentn Patients with Anal Carcinoma		Falkson		Wilson, Robyn RN		(205) 975-6347

*Bladder*	Top
*Also see Solid Tumor*

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
RTOG 0233		A Phase II Randomized Trial for Patients with Muscle-Invading Bladder Cancer Evaluating Transuretheral Surgery and BID Irradition Plus Either Paclitaxel and Cisplatin or 5-Flourouracil and Cisplatin Followed by Selective Bladder Preservation and Gemcitabine/Paclitaxel/Cisplatin Adjuvant Chemotherapy		Meredith		Oldham, Latania RN		(205) 975-2880

UAB 0516		Phase II Study of Isoflavone G-2535 (Genistein) in Patients with Bladder Cancer		Amling		Ayres, Linda LPN, CCRC		(205) 996-2613

*Brain Metastases*	Top
*Also see Solid Tumor*

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
RAD 0602		A Phase I Imaging and Safety Study of Intravenous 131 I-TM-601 Labeled-Chlorotoxin in Patients with Recurrent or Refractory Somatic and/or Cerebral Metastatic Solid Tumors		Fiveash		Suter, Susan RN		(205) 975-0868

*Brain/CNS*	Top

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
NABTT 0401		A Phase I Trial of BAY 43-9006 for Patients with Recurrent or Progressive Malignant Glioma		Nabors		Bell, Felecia		(205) 934-1848

RAD 0403		Phase V Gliasite Radiation System Registry Protocol for the Treatment of Resectable Malignant Brain Tumors		Fiveash		Suter, Susan RN		(205) 975-0868

UAB 0453		A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients with Recurrent High-Grade Glioma		Nabors		Bell, Felecia		(205) 934-1848

*Breast*	Top
*Also see Solid Tumor*

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
ECOG E1104		Phase I/II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination with Trastuzumab (Herceptin) in Patients with Advanced Metastatic and/or Local Chest Wall Recurrent Her-2 Amplified Breast Cancer		Falkson		Caterinicchia, Valerie, RN, BSN		(205) 934-5367

ECOG PACCT 1		Program for the Assessment of Clinical Cancer Tests (PACCT-1) Trial Assigning Individualized Options for Treatment: The TAILORx Trial		Falkson		Watters, Karen RN		(205) 996-2140

ECOG S0307		Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer		Falkson		Caterinicchia, Valerie, RN, BSN		(205) 934-5367

IBCSG 2402		A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer (SOFT Trial)		Falkson		Caterinicchia, Valerie, RN, BSN		(205) 934-5367

RTOG 0413		A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer		Meredith		Suter, Susan RN		(205) 975-0868

UAB 0461		The Study of Bevacizumab to Reverse Acquired Estrogen Independence in Metatstatic Breast Cancer Patients Previously Responsive to Hormonal Therapy: A Phase II Trial		Falkson		Caterinicchia, Valerie, RN, BSN		(205) 934-5367

UAB 0562		A Randomized Phase II Trial of Weekly vs. Every 2-Week vs. Every 3-Week Administration of ABI-007 in Combination with Bevacizumab in Women with Metastatic Breast Cancer		Forero-Torres		Caterinicchia, Valerie, RN, BSN		(205) 934-5367

UAB 0648		A Phase II, Randomized, Open Label Trial of Pre-Operative (Neoadjuvant) Letrozole (Femara) vs. Letrozole in Combination with Avastin in Post-Menopausal Women with Newly Diagnosed Operable Breast Cancer		Forero-Torres		Caterinicchia, Valerie, RN, BSN		(205) 934-5367

UAB 0710		Phase 2 Study to Investigate the Efficacy and Safety of ZK-Epothilone (ZK-Epo; ZK 219477) in Patients with Metatstatic Breast Cancer		Falkson		Caterinicchia, Valerie, RN, BSN		(205) 934-5367

*Colon*	Top
*Also see Solid Tumor*

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
ECOGE 5202		A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers		Falkson		Wilson, Robyn RN		(205) 975-6347

UAB 0661		A Phase 2 Study of Temozolomide (SCH52365) in Subjects with Advanced Aerodigestive Tract Cancers Selected for Methyltransferase (MGMT) Promoter		Conry		Ross, Teresa RN		(205) 978-2848

*Colorectal*	Top
*Also see Solid Tumor*

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
UAB 0661		A Phase 2 Study of Temozolomide (SCH52365) in Subjects with Advanced Aerodigestive Tract Cancers Selected for Methyltransferase (MGMT) Promoter		Conry		Ross, Teresa RN		(205) 978-2848

*Esophagus*	Top
*Also see Solid Tumor*

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
UAB 0661		A Phase 2 Study of Temozolomide (SCH52365) in Subjects with Advanced Aerodigestive Tract Cancers Selected for Methyltransferase (MGMT) Promoter		Conry		Ross, Teresa RN		(205) 978-2848

*Graft Vs Host Disease*	Top

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
UAB 0655		A Phase III, Randomized, Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Prochymal (Ex-Vivo, Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Steroid Refractory Acute GvHD		Ashraf		Williams, Lisa RN		(205) 934-0066

*Head and Neck*	Top
*Also see Solid Tumor*

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
RAD 0503		Phase III Trial of Erlotinib and Radiotherapy in Patients with Stage III Cutaneous Squamous Cell Carcinomas		Rosenthal		Suter, Susan RN		(205) 975-0868

RTOG 0522		A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) [Followed by Surgery for Selected Patients] for Stage III and IV Head and Neck Carcinomas		Meredith		Suter, Susan RN		(205) 975-0868

UAB 0529		A Phase 2, Open-Label Trial of the Safety and Biological Effect of Pre-Operative Peri-lymphatic Ultra Low Dose IRX-2 (with Cyclophosphamide, Indomethacin and Zinc) in Patients with Locally Advanced, Resectable Cancer of the Head and Neck		Carroll		Clemons, Lisa RN		(205) 934-9714

UAB 0661		A Phase 2 Study of Temozolomide (SCH52365) in Subjects with Advanced Aerodigestive Tract Cancers Selected for Methyltransferase (MGMT) Promoter		Conry		Ross, Teresa RN		(205) 978-2848

UAB 0718		Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer		Rosenthal		Clemons, Lisa RN		(205) 934-9714

*Hematologic*	Top

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
UAB 0341		A Phase I/II Study of Clofarbine & Cytosine Arabinoside (Ara-C) Remission Induction Therapy for Older Adults (60 years and older) with Newly Diagnosed Acute Myeloid Leukemia		Foran		Carlisle, Ronda RN, BSN		(205) 975-2511

UAB 0624		Standarization of CD3+ T-Cell Dose for Patients Receiving Allogeneic Peripherial Blood Hematopoietic Stem Cell Transplants from Matched Related Donors		Ashraf		Williams, Lisa RN		(205) 934-0066

UAB 0630		A Phase I Dose Escalation Study of SGN-35 in Patients with Relapsed/Refractory CD30 Positive Hematologic Malignancies		Forero-Torres		Connor, Jeanne RN, OCN		(205) 975-2944

UAB 0657		A Phase I/IIa Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of AT9283, a Small Molecule Inhibitor of Aurora Kinases, in Patients with Acute Leukemia, Chronic Myeloid Leukemia, High-Risk Myelodysplastic Syndromes or Myelofibrosis		Foran		Connor, Jeanne RN, OCN		(205) 975-2944

*Hypopharynx*	Top
*Also see Solid Tumor*

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
RTOG 0522		A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) [Followed by Surgery for Selected Patients] for Stage III and IV Head and Neck Carcinomas		Meredith		Suter, Susan RN		(205) 975-0868

UAB 0529		A Phase 2, Open-Label Trial of the Safety and Biological Effect of Pre-Operative Peri-lymphatic Ultra Low Dose IRX-2 (with Cyclophosphamide, Indomethacin and Zinc) in Patients with Locally Advanced, Resectable Cancer of the Head and Neck		Carroll		Clemons, Lisa RN		(205) 934-9714

UAB 0661		A Phase 2 Study of Temozolomide (SCH52365) in Subjects with Advanced Aerodigestive Tract Cancers Selected for Methyltransferase (MGMT) Promoter		Conry		Ross, Teresa RN		(205) 978-2848

UAB 0718		Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer		Rosenthal		Clemons, Lisa RN		(205) 934-9714

*Kidney*	Top
*Also see Solid Tumor*

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
ECOG E2805		A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma		Falkson		Gilbert, Debra RN		(205) 975-0073

UAB 0732		A Phase 1/2, Open-Label, Dose Escalation Study to Assess the Safety and Phamacokinetics of Recombinant Interleukin 21 (rIL-21) Administered Concomitantly with Sorafenib (Nexavar) in Subjects with Metastatic Renal Cell Carcinoma		Bolger		Gilbert, Debra RN		(205) 975-0073

*Larynx*	Top
*Also see Solid Tumor*

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
RTOG 0522		A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) [Followed by Surgery for Selected Patients] for Stage III and IV Head and Neck Carcinomas		Meredith		Suter, Susan RN		(205) 975-0868

UAB 0529		A Phase 2, Open-Label Trial of the Safety and Biological Effect of Pre-Operative Peri-lymphatic Ultra Low Dose IRX-2 (with Cyclophosphamide, Indomethacin and Zinc) in Patients with Locally Advanced, Resectable Cancer of the Head and Neck		Carroll		Clemons, Lisa RN		(205) 934-9714

UAB 0661		A Phase 2 Study of Temozolomide (SCH52365) in Subjects with Advanced Aerodigestive Tract Cancers Selected for Methyltransferase (MGMT) Promoter		Conry		Ross, Teresa RN		(205) 978-2848

UAB 0718		Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer		Rosenthal		Clemons, Lisa RN		(205) 934-9714

*Leukemia*	Top

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
UAB 0341		A Phase I/II Study of Clofarbine & Cytosine Arabinoside (Ara-C) Remission Induction Therapy for Older Adults (60 years and older) with Newly Diagnosed Acute Myeloid Leukemia		Foran		Carlisle, Ronda RN, BSN		(205) 975-2511

UAB 0657		A Phase I/IIa Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of AT9283, a Small Molecule Inhibitor of Aurora Kinases, in Patients with Acute Leukemia, Chronic Myeloid Leukemia, High-Risk Myelodysplastic Syndromes or Myelofibrosis		Foran		Connor, Jeanne RN, OCN		(205) 975-2944

UAB 0658		A Phase I Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AC220 when Administered Daily to Patients with Relapsed or Refractory Acute Myeloid Leukemia		Foran		Connor, Jeanne RN, OCN		(205) 975-2944

*Liver*	Top
*Also see Solid Tumor*

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
UAB 0708		A Pharmacokinetic Study of BMS-582664 in Subjects with Advanced Solid Malignancies and Normal Hepatic Function, and/or Hepatocellular Carcinoma with Impaired Hepatic Function		Posey		Wilson, Robyn RN		(205) 975-6347

*Lung*	Top
*Also see Solid Tumor*

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
RTOG 0212		A Phase II/III Randomized Trial of Two Doses (Phase III - Standard vs. High) and Two High Dose Schedules (Phase II - Once vs. Twice Daily) for Delivering Prophylactic Cranial Irradiation for Patients with Limited Disease Small Cell Lung Cancer		Meredith		Suter, Susan RN		(205) 975-0868

RTOG 0214		A Phase III Comparison of Prophylactic Cranial Irradiation versus Observation in Patients with Locally Advanced Non-Small Cell Lung Cancer		Meredith		Suter, Susan RN		(205) 975-0868

RTOG 0229		A Phase II Trial of Neoadjuvant Therapy with Concurrent Chemotherapy and High Dose Radiotherapy Followed by Surgical Resection and Consolidative Therapy for Locally Advanced Non-Small Lung Carcinoma		Meredith		Suter, Susan RN		(205) 975-0868

UAB 0421		Phase II Study of Dose-Intense Chemotherapy with Sequential Topoisomerase Targeting with Irinotecan/Oxaliplatin Followed by Etoposide/Carboplatin in Patients with Extensive Small Cell Lung Cancer		Robert		Prescott, Betty RN, OCN		(205) 975-9289

UAB 0476		Randomized Phase III Study of Docetaxel or Pemetrexed with or without Cetuximab in Patients with Recurrent or Progressive Non-Small Cell Lung Cancer after Platinum-Based Therapy		Robert		Prescott, Betty RN, OCN		(205) 975-9289

UAB 0557		Randomized, Double-Blind, Phase 2 Study of Erlotinib with or without SU011248 in the Treatment or Metastatic Non-Small Cell Lung Cancer		Robert		Messer, Anna RN		(205) 934-5092

UAB 0634		An Open-Label, Multicenter, Phase I/II Study of AT-101 in Combination with Topotecan in Patients with Relapsed or Refractory Small Cell Lung Cancer After Prior Platinum Containing First Line Chemotherapy		Robert		Prescott, Betty RN, OCN		(205) 975-9289

UAB 0649		Phase I Feasibility Study of the Combination of Fondaparinux (Arixtra) with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer		Robert		Prescott, Betty RN, OCN		(205) 975-9289

UAB 0661		A Phase 2 Study of Temozolomide (SCH52365) in Subjects with Advanced Aerodigestive Tract Cancers Selected for Methyltransferase (MGMT) Promoter		Conry		Ross, Teresa RN		(205) 978-2848

*Lymphoma*	Top

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
UAB 0475		A Phase I, Open-Label, Multi-Center, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetic Properties of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients with Advanced Malignancies		Forero-Torres		Carlisle, Ronda RN, BSN		(205) 975-2511

UAB 0614		Open-Label, Multicenter, Phase 1/2 Dose-Escalation Study of AME-133v (LY2469298), Administered Intavenously in Four Weekly Doses, in Subjects with CD20+ Follicular Relapsed or Refractory Non-Hodgkin''s Lymphoma		Forero-Torres		Carlisle, Ronda RN, BSN		(205) 975-2511

UAB 0615		A Phase 1/2 Study of CMC-544 Administered in Combination with Rituximab in Subjects with Follilcular or Diffuse Large B-Cell Non-Hodgkin's Lymphoma		Foran		Connor, Jeanne RN, OCN		(205) 975-2944

UAB 0651		A Phase II Study of SGN-40 (anti-huCD40 mAb) in Patients with Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)		Forero-Torres		Connor, Jeanne RN, OCN		(205) 975-2944

UAB 0745		Single Agent, Phase II Study of Forodesine (BCX1777) in the Treatment of Cutaneous T-Cell Lymphoma (BCX177-203)		Forero-Torres		Connor, Jeanne RN, OCN		(205) 975-2944

*Melanoma*	Top
*Also see Solid Tumor*

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
ECOG E1697		Phase III Randomized Study of Four Weeks High Dose IFN-a2b in Stage T2b N0, T3a-b, T4a-b N0, and T1-4, N1a,2a, 3 (microscopic) Melanoma		Falkson		Ross, Teresa RN		(205) 978-2848

ECOG E2602		Phase II Study of Low Dose Peginterferon Alfa-2b in Patients with Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor		Falkson		Ross, Teresa RN		(205) 978-2848

*Myelodysplastic Syndrome*	Top

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
UAB 0657		A Phase I/IIa Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of AT9283, a Small Molecule Inhibitor of Aurora Kinases, in Patients with Acute Leukemia, Chronic Myeloid Leukemia, High-Risk Myelodysplastic Syndromes or Myelofibrosis		Foran		Connor, Jeanne RN, OCN		(205) 975-2944

*Nasopharynx*	Top
*Also see Solid Tumor*

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
RTOG 0615		Phase II Study of Concurrent Chemoradiotherapy Using Three-Dimensional Conformal Radiotherapy or IMRT + Bevacizumab for Locally or Regionally Advanced Nasopharyngeal Cancer		Meredith		Oldham, Latania RN		(205) 975-2880

*Oral Cavity*	Top
*Also see Solid Tumor*

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
UAB 0529		A Phase 2, Open-Label Trial of the Safety and Biological Effect of Pre-Operative Peri-lymphatic Ultra Low Dose IRX-2 (with Cyclophosphamide, Indomethacin and Zinc) in Patients with Locally Advanced, Resectable Cancer of the Head and Neck		Carroll		Clemons, Lisa RN		(205) 934-9714

UAB 0661		A Phase 2 Study of Temozolomide (SCH52365) in Subjects with Advanced Aerodigestive Tract Cancers Selected for Methyltransferase (MGMT) Promoter		Conry		Ross, Teresa RN		(205) 978-2848

UAB 0718		Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer		Rosenthal		Clemons, Lisa RN		(205) 934-9714

*Oropharynx*	Top
*Also see Solid Tumor*

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
RTOG 0522		A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) [Followed by Surgery for Selected Patients] for Stage III and IV Head and Neck Carcinomas		Meredith		Suter, Susan RN		(205) 975-0868

UAB 0529		A Phase 2, Open-Label Trial of the Safety and Biological Effect of Pre-Operative Peri-lymphatic Ultra Low Dose IRX-2 (with Cyclophosphamide, Indomethacin and Zinc) in Patients with Locally Advanced, Resectable Cancer of the Head and Neck		Carroll		Clemons, Lisa RN		(205) 934-9714

UAB 0661		A Phase 2 Study of Temozolomide (SCH52365) in Subjects with Advanced Aerodigestive Tract Cancers Selected for Methyltransferase (MGMT) Promoter		Conry		Ross, Teresa RN		(205) 978-2848

UAB 0718		Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer		Rosenthal		Clemons, Lisa RN		(205) 934-9714

*Ovary*	Top
*Also see Solid Tumor*

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
UAB 0612		A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Arm Study of the Effect of Intravenous AVE005 (VEGF Trap) Administered Every 2 Weeks in Advanced Ovarian Cancer Patients with Recurrent Symptomatic Malignant Ascites		Barnes		Kilgore, Patricia RN		(205) 930-8644

UAB 0643		A Phase 1 Study of Tropism Modified Conditionally Replicative Adenovirus Vector (Ad5-Delta24RGD) for Intra-Pertioneal Delivery in Ovarian and Extra-Ovarian Cancer Patients		Alvarez		Kilgore, Patricia RN		(205) 930-8644

UAB 0703		A Phase I, Open-Label, Dose Escalation Study of the Safety and Preliminary Efficacy of EGEN 001 in Combination with Carboplatin and Docetaxel in Women with Recurrent, Platinum-Sensitive, Epithelilal Ovarian Cancer		Alvarez		Kilgore, Patricia RN		(205) 930-8644

UAB 0727		A Phase II Protocol of Carboplatin/Gemcitabine + Bevacizumab versus Placebo		Makhija		Kilgore, Patricia RN		(205) 930-8644

*Pancreas*	Top
*Also see Solid Tumor*

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
UAB 0560		A Phase I Study Evaluating the Role of Anti-Epidermal Growth Factor Receptor Antibody, C225, as a Radiosensitizer with Chemoradiation for Locally Advanced Pancreatic Cancer		Arnoletti		Craig, Dayle RN		(205) 975-8080

UAB 0601		A Phase 2 Double-Blind, Placebo Controlled, Multi-Center Adjuvant Trial of the Efficacy, Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant Saccharomyces cerevisiae Expressing Mutant Ras Protein Combined with a Gemcitabine Regimen Versus a Gemcitabine Regimen with Placebo, in Patients with Post-Resection R0/R1 Pancreatic Cancer with Tumor Sequence Confirmation of Ras Mutations		Arnoletti		Craig, Dayle RN		(205) 975-8080

UAB 0641		A Phase I Trial of Gemcitabine (Gemzar) Plus ABI-007 (Abraxane) in Patients with Advanced Metastatic Pancreatic Cancer		Wood		Wilson, Robyn RN		(205) 975-6347

UAB 0740		Phase 2, Multicenter, Open-Label Study of CS-1008, A Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5), in Combination with Gemcitabine in Chemotherapy Naive Subjects with Unresectable or Metastatic Pancreatic Cancer		Forero-Torres		Carlisle, Ronda RN, BSN		(205) 975-2511

*Prostate*	Top
*Also see Solid Tumor*

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
RTOG 0521		A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT vs AS and 3DCRT/IMRT Followed by Chemotherapy with Docetaxel and Prednisone for Localized, High-Risk Prostate Cancer		Meredith		Oldham, Latania RN		(205) 975-2880

UAB 0738		A Randomized, Double-Blind, Multicenter, Phase 2 Study of a Human Monoclonal Antibody to Human Alpha-5 Integrins (CNTO 95) in Combination with Docetaxel and Prednisone for the First-Line Treatment of Subjects with Metastatic Hormone Refractory Prostate Cancer		Bolger		Gilbert, Debra RN		(205) 975-0073

*Rectum*	Top
*Also see Solid Tumor*

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
ECOG E3205		Phase II Trial of Cetuximab Plus Cisplatin, 5-FU and Radiation in Immunocompetentn Patients with Anal Carcinoma		Falkson		Wilson, Robyn RN		(205) 975-6347

UAB 0661		A Phase 2 Study of Temozolomide (SCH52365) in Subjects with Advanced Aerodigestive Tract Cancers Selected for Methyltransferase (MGMT) Promoter		Conry		Ross, Teresa RN		(205) 978-2848

*Skin*	Top
*Also see Solid Tumor*

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
RAD 0503		Phase III Trial of Erlotinib and Radiotherapy in Patients with Stage III Cutaneous Squamous Cell Carcinomas		Rosenthal		Suter, Susan RN		(205) 975-0868

*Solid Tumors*	Top
*Also see Solid Tumor*

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
RAD 0408		Phase II Study of Spinal Radiosurgery		Fiveash		Suter, Susan RN		(205) 975-0868

UAB 0475		A Phase I, Open-Label, Multi-Center, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetic Properties of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients with Advanced Malignancies		Forero-Torres		Carlisle, Ronda RN, BSN		(205) 975-2511

UAB 0708		A Pharmacokinetic Study of BMS-582664 in Subjects with Advanced Solid Malignancies and Normal Hepatic Function, and/or Hepatocellular Carcinoma with Impaired Hepatic Function		Posey		Wilson, Robyn RN		(205) 975-6347

UAB 0734		Phase I Open-Label Multi-Center, Dose-Escalating, Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of SNS-314, a Novel Aurora Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors		Robert		Messer, Anna RN		(205) 934-5092

UAB 0739		A Phase I, Open-Label, Dose Escalation Study of the Humanized Monoclonal Antibody, TRC093, in Patients with Locally Advanced or Metastatic Solid Tumors		Robert		Carlisle, Ronda RN, BSN		(205) 975-2511

*Stomach/Gastric*	Top
*Also see Solid Tumor*

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
UAB 0717		A Phase 2 Study of XL880 Administered Orally to Patients with Poorly Differentiated Diffuse Metastatic Gastric Cancer		Posey		Craig, Dayle RN		(205) 975-8080

*Supportive Care*	Top

Protocol Number		Title		Principal Investigator		Nurse Contact		Phone
UAB 0654		Phase 3 Multicenter Study: Amelioration of Oral Mucositis Pain by NASA Near Infra Red Light Emitting Diodes in Bone Marrow Transplantation Patients		Vaughan		Williams, Lisa RN		(205) 934-0066

UAB 0723		Extended Deep Venous Thrombosis Prophylaxis in Gynecologic Oncology Surgery with Intermittent Compression Devices (ICD) with or without Post Operative Arixtra (fondaparinux sodium): A Randomized Controlled Trial		Huh		Kilgore, Patricia RN		(205) 930-8644